Restrepo A, Raez L E, Byrne G E, Johnson T, Ossi P, Benedetto P, Hamilton K, Whitcomb C C, Cassileth P A
Department of Medicine, University of Miami School of Medicine, FL, USA.
Crit Rev Oncog. 1998;9(3-4):269-73.
To examine the frequency of metastasis to the eye and central nervous system (CNS) from ocular adnexal lymphomas and to evaluate whether CNS prophylaxis is appropriate for these tumors.
Seventy-one patients with biopsy-confirmed ocular adnexal lymphomas were evaluated between 1989 and 1995. The lymphomas were subclassified histopathologically according to the new Revised European-American Lymphoma (REAL) criteria. Molecular genetic analysis of tumor cell DNA was done by Southern blot. Patients had a complete ophthalmologic evaluation and metastatic work-up and were then routinely followed up by an ophthalmologist and a medical oncologist.
The 34 men and 37 women studied had a median age of 67 years (23 to 92). Ocular adnexal lymphomas were situated in the orbit in 54 patients, in the conjunctiva in 14 patients, and in the eyelid in 3 patients. Bilateral involvement occurred in 11 patients. The most common histologic diagnoses were (54 patients, 76%) extra-nodal marginal zone lymphomas and small lymphocytic lymphomas in 10 patients (14%). Molecular genetic analysis performed in all patients confirmed a monoclonal B-cell population in 55 patients (77%), including a single rearrangement of the immunoglobulin heavy chain gene in 14 patients, and more than two rearrangements in 41 patients. No patients had isolated T-cell gene rearrangements. Localized ocular adnexal lymphoma was diagnosed in 43 patients (61%), 17 patients (24%) were found to have concurrent extraocular lymphoma on metastatic work-up and 11 patients (15%) had a previous diagnosis of systemic lymphoma before the onset of their ocular tumor. The median duration of follow-up was 20 months. Overall, 32 patients (45%) had tumors, which remained localized to the orbit adnexa. Eleven patients (15%) relapsed, but none had eye or central nervous system involvement nor required CNS-directed therapy. Although eight patients died, only two died as a direct result of systemic lymphoma. No patient received CNS prophylaxis with either intrathecal chemotherapy and/or radiation therapy.
Ocular adnexal lymphomas are rare non-Hodgkin's B-cell lymphomas. Metastatic involvement of the eye or central nervous system is rare and CNS prophylaxis with radiotherapy or chemotherapy is unnecessary.
研究眼附属器淋巴瘤转移至眼和中枢神经系统(CNS)的频率,并评估对这些肿瘤进行CNS预防性治疗是否合适。
对1989年至1995年间71例经活检确诊的眼附属器淋巴瘤患者进行评估。根据新的修订欧美淋巴瘤(REAL)标准对淋巴瘤进行组织病理学亚分类。通过Southern印迹法对肿瘤细胞DNA进行分子遗传学分析。患者接受了全面的眼科评估和转移灶检查,随后由眼科医生和肿瘤内科医生进行常规随访。
研究的34名男性和37名女性的中位年龄为67岁(23至92岁)。眼附属器淋巴瘤位于眼眶的有54例,位于结膜的有14例,位于眼睑的有3例。11例患者为双侧受累。最常见的组织学诊断为结外边缘区淋巴瘤54例(76%),小淋巴细胞淋巴瘤10例(14%)。对所有患者进行的分子遗传学分析证实55例患者(77%)存在单克隆B细胞群体,其中14例患者免疫球蛋白重链基因有单一重排,41例患者有两个以上重排。无患者有孤立的T细胞基因重排。43例患者(61%)诊断为局限性眼附属器淋巴瘤,17例患者(24%)在转移灶检查时发现合并眼外淋巴瘤,11例患者(15%)在眼部肿瘤发病前曾诊断为系统性淋巴瘤。中位随访时间为20个月。总体而言,32例患者(45%)的肿瘤局限于眼眶附件。11例患者(15%)复发,但均无眼部或中枢神经系统受累,也无需进行CNS导向治疗。虽然8例患者死亡,但仅2例直接死于系统性淋巴瘤。无患者接受鞘内化疗和/或放射治疗进行CNS预防性治疗。
眼附属器淋巴瘤是罕见的非霍奇金B细胞淋巴瘤。眼或中枢神经系统转移受累罕见,放疗或化疗进行CNS预防性治疗无必要。